Sativex approved in Sweden

Published: 22-Dec-2011
Regulatory

For the treatment of spasticity due to multiple sclerosis


The Medical Products Agency in Sweden has granted regulatory approval to GW Pharmaceuticals’ cannabis-based medicine Sativex as a treatment for moderate to severe spasticity due to multiple sclerosis.

Sativex (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray is currently available in the UK, Germany, Spain and Denmark.

Clinical trials have shown that the drug has a positive impact on spasticity in MS, while alleviating associated symptoms including pain, bladder or sleep disturbance.

Sativex is also in phase III clinical development for the treatment of cancer pain.

GW’s marketing partner Almirall will start marketing the drug in Sweden during the first half of 2012 following completion of the national pricing and reimbursement process.

Almirall holds the marketing rights to this medicine in Europe (except the UK).

  • Companies:
  • GW Pharmaceuticals
See more

You may also like

Regulatory

GW Pharmaceuticals gains product recognition by NHS England

Read more
Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Excellence

Trending Articles

  1. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  2. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  3. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  4. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  5. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

GW Pharmaceuticals gains product recognition by NHS England

Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Excellence
Manufacturing

Momentum in the US cannabidiol market gains retailers' attention

Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Regulatory

First prescription CBD from GW Pharma has restriction lowered

The US Drug Enforcement Administration’s decision to move Epidiolex to Schedule V was based on non-clinical and clinical data that evaluated the medicine’s potential for abuse
Regulatory

First plant-derived cannabinoid prescription gains FDA approval

GW Pharmaceuticals has announced FDA approval of EPIDIOLEX (cannabidiol) oral solution, a medication prescribed for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome
Regulatory

GW receives FDA fast track and EMA orphan designations for intravenous cannabidiol

FDA orphan designation previously granted for the neonatal hypoxic-ischaemic encephalopathy (NHIE) treatment
Regulatory

Sativex moved to Schedule 4 of UK Drugs Act

Recognises low potential for abuse and low risk of diversion
Regulatory

Sativex approved in Denmark

For the treatment of spasticity due to Multiple Sclerosis (MS)
Subscribe now